These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

292 related items for PubMed ID: 33293372

  • 1. Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET.
    Wang S, Li J, Hua J, Su Y, Beckford-Vera DR, Zhao W, Jayaraman M, Huynh TL, Zhao N, Wang YH, Huang Y, Qin F, Shen S, Gioeli D, Dreicer R, Sriram R, Egusa EA, Chou J, Feng FY, Aggarwal R, Evans MJ, Seo Y, Liu B, Flavell RR, He J.
    Clin Cancer Res; 2021 Mar 01; 27(5):1305-1315. PubMed ID: 33293372
    [Abstract] [Full Text] [Related]

  • 2. CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma.
    Wadhwa A, Wang S, Patiño-Escobar B, Bidkar AP, Bobba KN, Chan E, Meher N, Bidlingmaier S, Su Y, Dhrona S, Geng H, Sarin V, VanBrocklin HF, Wilson DM, He J, Zhang L, Steri V, Wong SW, Martin TG, Seo Y, Liu B, Wiita AP, Flavell RR.
    Clin Cancer Res; 2024 Mar 01; 30(5):1009-1021. PubMed ID: 38109209
    [Abstract] [Full Text] [Related]

  • 3. Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy.
    Bidkar AP, Wang S, Bobba KN, Chan E, Bidlingmaier S, Egusa EA, Peter R, Ali U, Meher N, Wadhwa A, Dhrona S, Dasari C, Beckford-Vera D, Su Y, Tang R, Zhang L, He J, Wilson DM, Aggarwal R, VanBrocklin HF, Seo Y, Chou J, Liu B, Flavell RR.
    Clin Cancer Res; 2023 May 15; 29(10):1916-1928. PubMed ID: 36917693
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Development of CD46 targeted alpha theranostics in prostate cancer using 134Ce/225Ac-Macropa-PEG4-YS5.
    Bobba KN, Bidkar AP, Wadhwa A, Meher N, Drona S, Sorlin AM, Bidlingmaier S, Zhang L, Wilson DM, Chan E, Greenland NY, Aggarwal R, VanBrocklin HF, He J, Chou J, Seo Y, Liu B, Flavell RR.
    Theranostics; 2024 May 15; 14(4):1344-1360. PubMed ID: 38389832
    [Abstract] [Full Text] [Related]

  • 6. Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial.
    Tendler S, Dunphy MP, Agee M, O'Donoghue J, Aly RG, Choudhury NJ, Kesner A, Kirov A, Mauguen A, Baine MK, Schoder H, Weber WA, Rekhtman N, Lyashchenko SK, Bodei L, Morris MJ, Lewis JS, Rudin CM, Poirier JT.
    Lancet Oncol; 2024 Aug 15; 25(8):1015-1024. PubMed ID: 38950555
    [Abstract] [Full Text] [Related]

  • 7. Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET.
    Ruggiero A, Holland JP, Hudolin T, Shenker L, Koulova A, Bander NH, Lewis JS, Grimm J.
    J Nucl Med; 2011 Oct 15; 52(10):1608-15. PubMed ID: 21908391
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cadherin-17 as a target for the immunoPET of adenocarcinoma.
    Delaney S, Keinänen O, Lam D, Wolfe AL, Hamakubo T, Zeglis BM.
    Eur J Nucl Med Mol Imaging; 2024 Jul 15; 51(9):2547-2557. PubMed ID: 38625402
    [Abstract] [Full Text] [Related]

  • 14. Translational Development of a Zr-89-Labeled Inhibitor of Prostate-specific Membrane Antigen for PET Imaging in Prostate Cancer.
    Vázquez SM, Endepols H, Fischer T, Tawadros SG, Hohberg M, Zimmermanns B, Dietlein F, Neumaier B, Drzezga A, Dietlein M, Schomäcker K.
    Mol Imaging Biol; 2022 Feb 15; 24(1):115-125. PubMed ID: 34370181
    [Abstract] [Full Text] [Related]

  • 15. A comparison of DFO and DFO* conjugated to trastuzumab-DM1 for complexing 89Zr - In vitro stability and in vivo microPET/CT imaging studies in NOD/SCID mice with HER2-positive SK-OV-3 human ovarian cancer xenografts.
    Cho H, Al-Saden N, Lam H, Möbus J, Reilly RM, Winnik MA.
    Nucl Med Biol; 2020 Feb 15; 84-85():11-19. PubMed ID: 31931305
    [Abstract] [Full Text] [Related]

  • 16. Noninvasive Imaging of PSMA in prostate tumors with (89)Zr-Labeled huJ591 engineered antibody fragments: the faster alternatives.
    Viola-Villegas NT, Sevak KK, Carlin SD, Doran MG, Evans HW, Bartlett DW, Wu AM, Lewis JS.
    Mol Pharm; 2014 Nov 03; 11(11):3965-73. PubMed ID: 24779727
    [Abstract] [Full Text] [Related]

  • 17. Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer.
    Su Y, Liu Y, Behrens CR, Bidlingmaier S, Lee NK, Aggarwal R, Sherbenou DW, Burlingame AL, Hann BC, Simko JP, Premasekharan G, Paris PL, Shuman MA, Seo Y, Small EJ, Liu B.
    JCI Insight; 2018 Sep 06; 3(17):. PubMed ID: 30185663
    [Abstract] [Full Text] [Related]

  • 18. Preclinical ImmunoPET Imaging Using a Zr-89-Labeled Anti-CD146 Monoclonal Antibody for Diagnosis of Melanoma.
    Guo X, Hu M, Zhang Q, Liu J, Shi J, Tang Y, Liu S, Guo J, Kong Y, Zhu H, Yang Z.
    Mol Pharm; 2024 Sep 02; 21(9):4490-4497. PubMed ID: 39077827
    [Abstract] [Full Text] [Related]

  • 19. Synthesis and Comparative In Vivo Evaluation of Site-Specifically Labeled Radioimmunoconjugates for DLL3-Targeted ImmunoPET.
    Sharma SK, Adumeau P, Keinänen O, Sisodiya V, Sarvaiya H, Tchelepi R, Korsen JA, Pourat J, Edwards KJ, Ragupathi A, Hamdy O, Saunders LR, Rudin CM, Poirier JT, Lewis JS, Zeglis BM.
    Bioconjug Chem; 2021 Jul 21; 32(7):1255-1262. PubMed ID: 33835770
    [Abstract] [Full Text] [Related]

  • 20. 89Zr-DFO-AMG102 Immuno-PET to Determine Local Hepatocyte Growth Factor Protein Levels in Tumors for Enhanced Patient Selection.
    Price EW, Carnazza KE, Carlin SD, Cho A, Edwards KJ, Sevak KK, Glaser JM, de Stanchina E, Janjigian YY, Lewis JS.
    J Nucl Med; 2017 Sep 21; 58(9):1386-1394. PubMed ID: 28280216
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.